Sörensen, Nils A. http://orcid.org/0000-0002-7571-4847
Nikorowitsch, Julius
Neumann, Johannes T.
Rübsamen, Nicole
Goßling, Alina
Hartikainen, Tau S.
Blankenberg, Stefan
Westermann, Dirk
Zeller, Tanja
Karakas, Mahir
Clinical trials referenced in this document:
Documents that mention this clinical trial
Performance of the ESC 0/1-h and 0/3-h Algorithm for the Rapid Identification of Myocardial Infarction Without ST-Elevation in Patients With Diabetes (Results)
https://doi.org/10.2337/dc19-1327
Long-term outcome of patients presenting with myocardial injury or myocardial infarction
https://doi.org/10.1007/s00392-023-02334-w
Diagnostic performance of a device for acoustic heart sound analysis in patients with suspected myocardial infarction
https://doi.org/10.1136/openhrt-2022-002090
Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction
https://doi.org/10.1007/s00392-019-01475-1
Personalized diagnosis in suspected myocardial infarction
https://doi.org/10.1007/s00392-023-02206-3
Funding for this research was provided by:
Abbott Laboratories (xxx)
German Center of Cardiovascular Research (81Z1710101)
Deutsche Herzstiftung (F/42/16)
Deutsche Stiftung für Herzforschung (2017_A143)
Article History
Received: 4 February 2019
Accepted: 4 April 2019
First Online: 16 April 2019
Compliance with ethical standards
:
: Dr. Neumann received honoraria from Siemens and Abbott Diagnostics. Dr. Blankenberg received honoraria from Abbott Diagnostics, Siemens, Thermo Fisher, and Roche Diagnostics and is a consultant for Thermo Fisher. Dr. Westermann reports personal fees from Bayer, Boehringer-Ingelheim, Berlin Chemie, AstraZeneca, Biotronik and Novartis. Dr. Karakas received consultancy fees outside of the scope of this manuscript from Vifor Pharma, Amgen, Sanofi, and AstraZeneca, and furthermore Grant support from Vifor Pharma.